Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006226 · ClinicalTrials.gov registry record · Phase 2
Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00006226: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00006226 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006226, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of thalidomide in treating patients who have relapsed chronic lymphocytic leukemia. Thalidomide may stop the growth of chronic lymphocytic leukemia by stopping blood flow to the tumor.
Interventions
- OTHER laboratory biomarker analysis
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2000-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006226
The ClinicalTrials.gov registry entry for NCT00006226 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00006226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006226 about?
NCT00006226 is a clinical study titled "Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia". Phase II trial to study the effectiveness of thalidomide in treating patients who have relapsed chronic lymphocytic leukemia. Thalidomide may stop the growth of chronic lymphocytic leukemia by stopping blood flow to the tumor.
What is the current status of trial NCT00006226?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2000-09.
What interventions are being tested in trial NCT00006226?
The interventions under investigation include: laboratory biomarker analysis (OTHER), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00006226?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.